BACKGROUND:Accurate detection and local staging of prostate cancer (PCa) remain critical for treatment planning, yet head-to-head multimodal imaging comparisons remain limited. OBJECTIVE:This study compared microultrasound (microUS), multiparametric magnetic resonance imaging (mpMRI), and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for detecting clinically significant PCa (csPCa) and extraprostatic extension (EPE), using whole-mount histopathology (WMHP) as the reference standard. DESIGN, SETTING, AND PARTICIPANTS:This retrospective study included patients who underwent microUS and mpMRI followed by radical prostatectomy between January 2023 and October 2024. A subset also underwent PSMA PET/CT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:Detection of csPCa and EPE was assessed at the lesion and sector levels using WMHP as a reference. Detection rates and positive predictive values (PPVs) were compared using McNemar and chi-square tests, while sector-level area under the receiver operating characteristic curves (AUCs) were compared using the DeLong test. RESULTS AND LIMITATIONS:No statistically significant differences were observed between microUS and mpMRI or PSMA PET/CT for index lesion detection (0.90, 0.94, and 0.93, respectively) or csPCa detection (0.71, 0.78, and 0.72, respectively), although the study may have been underpowered to detect small differences. mpMRI had higher PPVs for csPCa than microUS (0.91 vs 0.77, p = 0.03). mpMRI achieved the highest sector-level AUCs for csPCa (0.73) and EPE (0.88). Across modalities, 15-18% of csPCa lesions were missed, which were non-index Grade Group 2 with Gleason pattern 4 ≤20%. The study is limited by its single-center retrospective design. CONCLUSIONS:MicroUS showed no statistically significant differences compared with mpMRI and PSMA PET/CT for detecting index and csPCa lesions, supporting a potential complementary role in resource-limited or MRI-contraindicated settings.

Abstract Antibody-drug conjugates (ADCs) enable the selective delivery of highly cytotoxic payloads to tumors and are emerging as new, promising therapeutic options for prostate cancer. Prostate stem cell antigen (PSCA) is a cell-surface antigen that is highly overexpressed in prostate cancer and upregulated in advanced disease states, while minimally expressed in normal tissues, making it an ideal target for ADC therapy. In this study, we identified and generated full-length human anti-PSCA antibodies, exhibiting high binding affinity and rapid internalization into PSCA-expressing cancer cells. Various cytotoxic drugs (e.g., monomethyl auristatin E (MMAE), DM1, etc.) were conjugated to the lead anti-human PSCA antibody (A2) using a chemically validated linker. Among the resulting ADC candidates, A2-MMAE demonstrated the most potent, concentration-dependent cytotoxicity against PSCA-positive human prostate cancer cell lines, with an IC50 range of 0.18-2.17 nM, while exhibiting no cytotoxicity in PSCA-negative cells. Hydrophobic interaction chromatography (HIC-HPLC) analysis revealed a heterogeneous distribution of drug-to-antibody ratios (DARs), with an average DAR of 4.84. Furthermore, A2-MMAE retained a high level of total ADC integrity following 10 days of incubation in mouse plasma, indicating a robust plasma stability. These findings suggest that the novel anti-PSCA ADC (anti-PSCA-VC-PAB-MMAE), characterized by its strong target specificity, high potency, and excellent stability, holds promise as a safer and more effective therapeutic for prostate cancer. Ongoing studies will evaluate its in vivo antitumor efficacy, tolerability, safety, and pharmacokinetic/pharmacodynamic (PK/PD) profiling in mouse models. Citation Format: Yanyang Cao, Evelyn A. Kono, Robert E. Reiter, . Development of a novel PSCA-targeting antibody-drug conjugate with high potency and stability for prostate cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1659.

BACKGROUND AND OBJECTIVE:A recent individual patient data (IPD) meta-analysis of randomized trials found a limited overall survival (OS) and metastasis-free survival (MFS) benefit to the addition of hormonal therapy (HT) to postoperative radiotherapy for prostate cancer in patients with pre-radiotherapy prostate-specific antigen (PSA) ≤0.5 ng/ml. We evaluated whether the OS and MFS benefits of adding HT might be significantly modified by an increasing count of adverse pathological features (adverse feature count [AFC]). METHODS:We obtained IPD from five randomized phase 3 trials of postoperative radiotherapy ± HT. AFC was prospectively defined as the sum (0-4) of grade group 4-5 disease, seminal vesicle invasion, positive surgical margins, and extracapsular extension. Intention-to-treat one-stage meta-analytical models were used. We also evaluated the interaction of the benefit of HT with a restricted score comprising only GG4-5 and seminal vesicle invasion (range 0-2), as a pre-specified sensitivity analysis. KEY FINDINGS AND LIMITATIONS:We included IPD from 4781 patients with a median follow-up of 9.1 yr. AFC was independently prognostic for OS and MFS. However, AFC did not significantly modify the OS benefit of HT (interaction hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.79-1.10; p = 0.4) or MFS benefit (interaction HR, 0.88; 95% CI, 0.77-1.01; p = 0.08). Results were similar when AFC was analyzed categorically and in high-risk subsets, and when the restricted AFC score was used. CONCLUSIONS AND CLINICAL IMPLICATIONS:Overall, the data suggest that although adverse pathological features are prognostic, they do not appear predictive of HT benefit after postoperative radiotherapy, which is relevant for patients with a PSA ≤0.5 ng/ml before radiation.

BACKGROUND:Adding hormone therapy to definitive radiotherapy in localised prostate cancer improves overall survival, but whether it similarly improves overall survival in the context of postoperative radiotherapy (PORT) after radical prostatectomy is unclear. Herein, we report an individual patient data (IPD) meta-analysis of randomised trials aimed at quantifying the benefit of adding hormonal therapy to PORT. METHODS:This was an IPD meta-analysis that identified randomised, phase 3 trials of PORT with or without hormone therapy. A systematic literature search of MEDLINE, Embase, trial registries, the Web of Science, Scopus, and relevant conference proceedings was done on Dec 15, 2024. IPD were available via the MARCAP consortium. The primary outcome was overall survival. Meta-analyses evaluated the benefit of adding hormone therapy, short-term hormone therapy (4-6 months), or long-term hormone therapy (24 months) to PORT. Tests for interaction based on pre-PORT prostate-specific antigen (PSA) and duration of hormone therapy were evaluated and non-linear associations between pre-PORT PSA and overall survival were modelled. This study was done under the master protocol of the MARCAP Consortium (PROSPERO registration CRD42019134376). FINDINGS:IPD were available for six randomised trials including 6057 patients with a median follow-up of 9·0 years (IQR 7·2-10·7 years). Adding hormone therapy to radiotherapy did not significantly improve overall survival (hazard ratio [HR] 0·87, 95% CI 0·76-1·01, p=0·06). There was no significant interaction between hormone therapy duration and this effect (pinteraction=0·17), although there was a significant interaction with pre-PORT PSA greater than 0·5 ng/mL versus 0·5 ng/mL or less (pinteraction=0·02). For all pre-PORT PSA values, the upper bounds of the 95% CI of the HR for overall survival crossed 1·0 for patients randomly assigned to PORT with or without short-term hormone therapy (n=3938). For patients randomly assigned to PORT with or without long-term hormone therapy (n=1088), the upper bounds of the 95% CI for overall survival HR fell below 1·0 at PSA greater than 1·6 ng/mL. INTERPRETATION:Our findings, we believe, provide the strongest level of evidence to date suggesting there might be no meaningful overall survival benefit to adding hormone therapy, either short-term or long-term hormone therapy, to PORT for PSA 0·5 ng/mL or less, with no apparent difference in efficacy for short-term versus long-term hormone therapy. There is an unmet need to identify biomarkers to predict potential hormone therapy benefit. FUNDING:National Institutes of Health.

BACKGROUND:Salvage radiotherapy (sRT) is the standard of care for biochemical recurrence of prostate cancer following radical prostatectomy (RP). In this context, prostate-specific membrane antigen (PSMA) PET/CT offers superior sensitivity and specificity for the detection of recurrent disease. We aimed to evaluate the impact of PSMA PET/CT-guided management on clinical outcomes following sRT. PATIENTS AND METHODS:We retrospectively screened 5 prospective PSMA PET/CT studies conducted between 2016 and 2021. Eligible patients underwent PSMA PET/CT for restaging at first biochemical recurrence after RP, received sRT, and had ≥24 months of follow-up. Progression-free survival (PFS), freedom from distant progression, and overall survival (OS) were calculated using the Kaplan-Meier method. Adjusted hazard ratios (aHRs) for PFS were derived using Cox proportional hazards regression, adjusting for age, pre-sRT prostate-specific antigen (PSA) level, use of androgen deprivation therapy (ADT), and receipt of whole-pelvis radiotherapy (WPRT). RESULTS:Of the total cohort, 113 patients met the inclusion criteria. Median follow-up was 59.4 months (IQR, 47.4-69.5). Median PSA was 0.4 ng/mL (IQR, 0.3-1.1), and the median time from RP was 19.9 months (IQR, 5.6-51.8). On PSMA PET/CT, 19 (16.8%) patients were staged as TrN0M0, 32 (28.3%) as N1M0, 16 (14.2%) as M1, and 46 (40.7%) as T0N0M0 (no visible disease). ADT was administered to 76 (67.3%) patients, and 63 (55.8%) patients received WPRT. Disease progression occurred in 57 (50.4%) patients. Median PFS was 49.2 months (95% CI, 24.1-74.3), and median freedom from distant progression was 76.4 months (95% CI, 62.9-89.9). The 5-year OS rate was 97.1% (95% CI, 94.1%-100%). Receipt of WPRT was significantly associated with improved PFS among patients staged as TrN0M0 (aHR, 0.12; P=.035), whereas ADT was significantly associated with improved PFS in patients staged as N1/M1 (aHR, 0.37; P=.024). CONCLUSIONS:In this 5-year follow-up study from an institution that was an early adopter of PSMA PET/CT, PSMA PET/CT-guided sRT was associated with favorable oncologic outcomes. Exploratory analyses suggest a potential benefit of WPRT following a positive PSMA PET/CT and of ADT in patients with N1/M1 disease.

Abstract Background Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly used to characterize newly diagnosed prostate cancer on the assumption that uptake highlights aggressive disease. However, maximum standardized uptake value (SUVmax) varies widely across localized tumors. Recent genomic assessments have suggested SUVmax reflects tumor biology even when accounting for other tumor indices. Here, we examined highly annotated pathologic, imaging and clinical correlates of intraprostatic SUVmax at the level of individual tumor foci in a prospective multimodal cohort. Methods Exploratory lesion-level analysis of the radical prostatectomy arm of a single-center prospective diagnostic-accuracy trial ( NCT04461509 ). Patients underwent simultaneous 18 F-DCFPyL PSMA PET, multiparametric magnetic resonance imaging (MRI) and high-resolution MRI before prostatectomy, with central blinded pathology and imaging review. Grade Group (GG) ≥2 foci measuring ≥10 mm were eligible. The primary outcome was focus-level SUVmax. Correlates spanning histology, tumor microenvironment, MRI and clinical indices were examined by Spearman correlation and rank-based group comparison, followed by separate linear regressions of log(1+SUVmax) each adjusted for GG and tumor size. A digital-pathology sensitivity analysis quantified immune, stromal and tumor pixel-area fractions on hematoxylin and eosin (H&E) sections from a subset of foci using a trained QuPath classifier. Results Twenty-seven patients contributed 34 tumor foci, of which 21 (61.8%) were GG2. Median SUVmax was 5.7 (interquartile range [IQR] 3.9–12.1; range 0.0–57.9). SUVmax rose across the cribriform/intraductal carcinoma (Crib/IDC) gradient (median 3.9, 4.8 and 10.2 for absent, focal and extensive; p = 0.010), correlated with % Gleason pattern 4 (ρ = +0.47, p = 0.005) and correlated inversely with stromal content (ρ = −0.40, p = 0.020). Grade Group (p = 0.115), Prostate Imaging Reporting and Data System (PI-RADS) 4 versus 5 (p = 0.705), standard apparent diffusion coefficient (ADC) (ρ = −0.27, p = 0.130), baseline prostate-specific antigen (PSA) (ρ = +0.04, p = 0.816) and PSA density (ρ = −0.02, p = 0.918) were not associated with SUVmax. In separate models of log(1+SUVmax) adjusted for Grade Group and tumor size, % Gleason pattern 4 remained associated with uptake (standardized β = +0.76, 95% CI +0.11 to +1.41), Crib/IDC (β = +0.36, −0.03 to +0.74), and stromal content (β = −0.30, −0.62 to +0.02). On 18 slides re-quantified by pixel classifier, no pixel-based compartment fraction correlated with SUVmax (immune ρ = −0.06, stroma ρ = +0.02, tumor ρ = −0.04; all p > 0.5). Conclusions In this prospective lesion-level cohort, intraprostatic PSMA SUVmax was associated with increased Gleason pattern 4 and cribriform/intraductal burden but not with other common risk indices. SUVmax therefore appears to carry information additive to conventional risk factors. Further investigations examining the tumor biology that reflects SUVmax are warranted.

Prostate cancer (PCa) is one of the most common malignancies affecting the male reproductive system. Robot-assisted radical prostatectomy (RARP) has been a standard treatment for PCa for over 20 years. However, postoperative urinary incontinence remains a frequent complication for patients who undergo RARP. Numerous surgical techniques have been developed to improve postoperative continence recovery, broadly categorized into preservation and reconstruction methods. Preservation techniques include safeguarding the bladder neck, distal urethra, detrusor apron, retropubic space, neurovascular bundles, and controlling the dorsal venous complex. Reconstruction techniques aim to mitigate the impairment of urethral sphincter function caused by surgery. While these approaches substantially enhance post-RARP urinary continence recovery, challenges remain in tailoring surgical plans to individual patient needs. This review explores the application of these representative techniques, discusses their current limitations, and highlights potential directions for future advancement.

Multimodal strategies combining primary and metastasis-directed therapy (MDT) with short-term intensified systemic therapy may improve outcomes in oligometastatic castrate-sensitive prostate cancer (omCSPC) while minimizing long-term toxicity. This post hoc analysis of two prospective phase 2 trials, SOLAR (NCT03298087) and SATURN (NCT03902951), evaluated oncologic outcomes in prostate-specific membrane antigen positron emission tomography-defined synchronous and metachronous omCSPC (≤5 M1a-b lesions), respectively. All patients received 6 mo of intensified systemic therapy (leuprolide, abiraterone acetate with prednisone, and apalutamide) and stereotactic body radiotherapy to oligometastases. SOLAR patients were treatment-naïve and also underwent radical prostatectomy (RP) or definitive prostate-directed radiotherapy (dRT). SATURN enrolled patients with post-RP recurrences: among the 26 patients who completed protocol therapy, 12 (46%) had prior androgen deprivation therapy (ADT), six (23%) had prior MDT, and 17 (65%) had one to three prior recurrences. The primary endpoint for both studies was prostate-specific antigen (PSA) response, defined as <0.05 ng/ml after RP or <2 ng/ml after dRT at 6 mo after testosterone recovery (≥150 ng/dl). Secondary endpoints included progression-free survival (PFS) and eugonadal PFS starting from the time of testosterone recovery. Progression was determined biochemically using PSA thresholds of ≥0.05 ng/ml for post-RP and ≥2 ng/ml for post-dRT patients. Among 50 patients (24 synchronous and 26 metachronous), the synchronous omCSPC group had a significantly higher PSA response rate (83% vs 50%; p = 0.018) and significantly longer PFS and eugonadal PFS (p < 0.05). The metachronous subgroup with prior ADT had worse outcomes, suggesting increasing resistance with repeated systemic therapy.

PURPOSE:Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy to SBRT would improve outcomes. METHODS:The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted at the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically at prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959). RESULTS:From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177Lu + SBRT n = 45). At a median follow-up of 22 months, the addition of 177Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177Lu + SBRT group). Prognostic biomarkers for PFS were identified. CONCLUSION:Compared with SBRT alone, the addition of 177Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.

BACKGROUND:Nearly 12% of patients in the United States with intermediate-risk prostate cancer (PCa) opt for surveillance as their initial management strategy. Patients with aggressive histologic variants, such as cribriform and intraductal carcinoma (IDC), are considered poor candidates for surveillance. The objective of this study was to determine the sensitivity and specificity of magnetic resonance imaging (MRI)-assisted biopsy for detecting cribriform PCa and IDC. METHODS:In this retrospective cohort study, patients who underwent prostate MRI before biopsy within 6 months of prostatectomy at a single institution (2018-2024) were identified. All patients had grade group 2-3 (GG2-3) PCa on biopsy. The primary outcome was the sensitivity of MRI-assisted biopsy for detecting cribriform PCa and IDC by patient in the prostatectomy specimen. RESULTS:The authors identified 641 patients who had 1186 tumors that were GG2-3 PCa on biopsy. The median time between MRI and biopsy was 31 days, and the median time between biopsy and surgery was 91 days. Cribriform PCa was identified in 35 patients (5.5%) at the time of biopsy and in 119 patients (18.6%) at surgery. IDC was present in 22 patients (3.4%) at biopsy and in 71 patients (11.1%) at surgery. By patient, the sensitivity for detecting cribriform PCa, IDC, or either was 21.8%, 26.8%, and 29.3%, respectively. The sensitivity by tumor for cribriform PCa, IDC, or either was 20.5%, 27.3%, and 28%, respectively. CONCLUSIONS:The sensitivity of MRI-assisted biopsy for detecting cribriform PCa and IDC in patients with GG2-3 PCa is poor. This work should encourage improvements in detecting variant histologies with optimized biopsy, imaging, and adjunct biomarkers.

Quantitative 3-T multiparametric MRI parameters correlated with and helped predict the presence of aggressive large cribriform pattern and intraductal carcinoma prostate cancer at whole-mount histopathology.

BACKGROUND AND OBJECTIVE:Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. METHODS:Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members ("panellists"). KEY FINDINGS AND LIMITATIONS:Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. CONCLUSIONS AND CLINICAL IMPLICATIONS:The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

A novel deep learning–based method for intrapatient multimodal image registration was developed that achieved high performance in aligning prostate MR and whole-mount histopathology images, facilitating accurate prostate cancer mapping.

Purpose The biology of locally radiorecurrent prostate cancer (LRR-PCa) is poorly understood. Methods and Materials We sought to explore the genomic and transcriptomic landscape of LRR-PCa with targeted DNA sequencing and RNA expression analysis from 41 biopsy-proven LRR-PCa tumors from 36 unique patients who had a recurrence at a median interval of 84 months (IQR, 70-124 months). Genomic alteration frequencies and transcriptomic data were compared between the LRR-PCa cohort and treatment-naïve patients from the Cancer Genome Atlas (genomic; n = 496) and Gleason grade-at-recurrence-matched patients from the Decipher Genomics Resource for Intelligent Discovery (transcriptomic; n = 22,320). Results Twenty-five patients (69%) had pathologic upgrading at recurrence (17% vs 64% with Gleason grade 4-5 disease; P < .001). The LRR-PCa cohort demonstrated significantly greater single-nucleotide variations in 29 genes known to be associated with prostate cancer, including several associated with increased aggressiveness and DNA repair: FAT1 (58.5% vs 1.0%), RAD51B (36.6% vs 0.4%), POLQ (34.1% vs 1.4%), KMT2C (34.1% vs 4.9%), BRCA2 (29.3% vs 1.8%), ATRX (26.8% vs 0.8%), and BRCA1 (24.4% vs 0.4%) (Pvalues < .001 for all). The LRR-PCa cohort had a significantly higher Decipher score (median, 0.80 vs 0.66; P = .05) and demonstrated significantly greater basal subtype based on PAM50 (56% vs 20%; P < .001) and lower androgen receptor activity (61% for LRR vs 9%; P < .001). Conclusions Overall, these results suggest that LRR-PCa has a distinct genomic and transcriptomic landscape from de novo prostate cancer. Specifically, LRR-PCa has an enrichment in SNVs in genes associated with tumor aggressiveness and/or DNA repair, has higher Decipher scores, a more basal subtype, and has transcriptomic evidence of lower androgen receptor activity and loss of tumor suppressor genes.

BACKGROUND AND OBJECTIVE:It is thought that androgen deprivation therapy (ADT) resistance and subsequent prostate cancer progression via epithelial-mesenchymal transition (EMT) is induced by the SRC and MEK pathways. We hypothesized that inhibition of these pathways could reduce EMT. METHODS:In this phase 2 trial, 45 patients undergoing prostatectomy for International Society of Urological Pathology grade group ≥3, prostate-specific antigen >20 ng/ml, and/or stage ≥cT3a localized prostate adenocarcinoma were randomized 1:1:1 to receive 6-8 wk of neoadjuvant ADT (enzalutamide + degarelix) alone or in combination with either an SRC inhibitor (dasatinib) or MEK inhibitor (trametinib). The primary endpoint was the abundance of EMT markers (N-cadherin and vimentin) on immunohistochemistry (IHC) after prostatectomy. Secondary outcomes included clinicopathologic outcomes, changes in EMT markers between biopsy and prostatectomy according to IHC and RNA abundance, and safety. KEY FINDINGS AND LIMITATIONS:IHC results for N-cadherin and vimentin after treatment did not differ by arm. No differences were observed in time to biochemical recurrence, time to testosterone recovery, or pathologic minimal residual disease. MAP2K1, MAP2K2, and SRC RNA abundance decreased significantly in all three arms. No patients experienced a grade ≥3 treatment-related adverse event. CONCLUSIONS AND CLINICAL IMPLICATIONS:Neoadjuvant SRC or MEK inhibition does not appear to mitigate the EMT response to ADT or influence clinical or pathological outcomes.

List of Differentially expressed genes in the subtypes of mCRPC in comparison with AR+/NE- tumors